Contact this trialFirst, we need to learn more about you.
Proteasome Inhibitor
Carfilzomib + Pomalidomide + Dexamethasone + Daratumumab for Multiple Myeloma
Recruiting1 awardPhase 1 & 2
Toronto, Ontario
This trial is investigating adding two drugs, carfilzomib and daratumumab, to the combination of pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service